SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like New Kid Tmunity Banks $100M From Gilead and Facebook Billionaire Sean Parker January 22, 2018 Debt-Ridden Valeant Nears Sale of Its $2 Billion Eye Care Biz Bausch & Lomb June 6, 2017 3 Biotechs That Have Investors Grinning at Thanksgiving Dinner This Year November 20, 2017